Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
A gain of function mutation in SHP2, a protein phosphatase encoded by PTPN11, causes Noonan syndrome (NS), which is characterized in part by developmental deficits in both the cardiac and skull fields. Previously, we found that expression of the mutated protein SHP2 Q79R in the heart led to a phenotypic presentation that mimicked some aspects of NS and that this was dependent upon activation of the ERK1/2 pathway. To understand the role that ERK1/2 signaling plays in skull development through signaling in the neural crest, we explored the consequences of Q79R expression in neural crest cells, which contribute to a subset of the bony and cartilaginous structures of the skull. Hyperactivation of ERK1/2 led to craniofacial defects that included smaller skull lengths, greater inner canthal distances, and taller frontal bone heights. In proportion to the smaller skull length, mandibular bone length was also reduced. Inhibition of ERK1/2 hyperactivity as a result of Q79R expression was achieved by injection of the MAPK/ERK kinase inhibitor U0126 during pregnancy. The drug effectively decreased the severity of the craniofacial defects and restored normal skull shape and fontanelle closure. X-ray computer-assisted microtomography analysis of the head confirmed that decreasing ERK1/2 activity led to an abrogation of the craniofacial deficits and brain shape changes that presented in the mice. These data show that normal ERK1/2 signaling in the neural crest is imperative for normal craniofacial development and offer insight into how the heart and craniofacial developmental fields might be affected in some congenital syndromic presentations.
Nakamura
Tomoki
T
Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA.
Gulick
James
J
Pratt
Ronald
R
Robbins
Jeffrey
J
D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D019465:Craniofacial Abnormalities / Q000201:enzymology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D051379:Mice; D008822:Mice, Transgenic; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009432:Neural Crest / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D009634:Noonan Syndrome / Q000378:metabolism*; D011247:Pregnancy; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D055114:X-Ray Microtomography
D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; C113580:U 0126; D048052:Mitogen-Activated Protein Kinase 3; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11
Birth Defects Res C Embryo Today. 2007 Dec;81(4):297-304
18228258
J Cell Sci. 2005 Jul 15;118(Pt 14):2997-3002
16014377
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18930-5
19017799
Dev Cell. 2007 Apr;12(4):645-52
17420000
Clin Pediatr (Phila). 1994 Sep;33(9):548-55
8001324
Cancer Sci. 2008 Jul;99(7):1319-25
18452557
Expert Rev Mol Med. 2003 Jan 29;5(4):1-17
14987407
Dev Biol. 2002 Jan 1;241(1):106-16
11784098
J Clin Invest. 2007 Aug;117(8):2123-32
17641779
Nat Rev Genet. 2001 Jun;2(6):458-68
11389462
Development. 1994 Aug;120(8):2213-24
7925022
Nat Genet. 2001 Dec;29(4):465-8
11704759
Cancer Metastasis Rev. 2008 Jun;27(2):179-92
18286234
J Anat. 2005 Nov;207(5):637-53
16313397
Nat Genet. 2001 Jan;27(1):17-8
11137991
Am J Hum Genet. 2002 Jun;70(6):1555-63
11992261
Nat Genet. 1997 Jan;15(1):36-41
8988166
J Bone Miner Res. 2006 Sep;21(9):1331-8
16939391
Adv Anat Embryol Cell Biol. 2003;169:III-VI, 1-138
12793205
Circulation. 2008 Mar 18;117(11):1423-35
18316486
Hum Mol Genet. 1996 Dec;5(12):1915-20
8968743
J Embryol Exp Morphol. 1986 Nov;98:21-58
3655649
Dev Dyn. 2006 Sep;235(9):2353-75
16680722
Bioessays. 1993 Apr;15(4):221-30
8517851
Nat Med. 2004 Aug;10(8):849-57
15273746
Development. 2003 Oct;130(19):4527-37
12925581
J Cell Biol. 2007 Feb 26;176(5):709-18
17325210